ERK1/2 inhibitor 13

ERK1/2 inhibitor 13 (Compound 21y) is the orally active inhibitor for ERK that inhibits ERK1 and ERK2 with IC50 of 91.71 nM and 97.87 nM. ERK1/2 inhibitor 13 inhibits the proliferation of MCF-7, 4T1, MDA-MB-468, and HCC1970 (IC50 of 0.67, 2.76, 2.15 and 1.68 μM), inhibits the cancer cell migration, induces apoptosis and autophagy in MCF-7. ERK1/2 inhibitor 13 exhibits antitumor and anti-metastatic effect in 4T1 xenograft mouse model[1].

Product Specifications

CAS Number

[3093367-23-5]

UNSPSC

12352005

Target

Apoptosis; Autophagy; ERK

Related Pathways

Apoptosis; Autophagy; MAPK/ERK Pathway; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Smiles

FC(F)(C1=CC(NC(N[C@@H](CC2=CC=CC=C2)CN3C=[N+](CC4=CC=CC5=C4C=CC=C5)C6=C3C=CC=C6)=O)=CC(C(F)(F)F)=C1)F.[Br-]

Molecular Formula

C36H29BrF6N4O

Molecular Weight

727.54

References & Citations

[1]Wang M, et al., Discovery of Novel Aromatic Urea-Imidazole Salt Derivatives for Cancer Therapy via Targeting ERK1/2. J Med Chem. 2025 Feb 27;68 (4) :4101-4132.